drugset

drugset / Trial / NCT04358224

The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment

NCT04358224 ↗

Phase 4 Completed 12 enrolled Jonathan A. Bernstein, MD

NaSingle-groupOpen-labelTreatment

Summary

The utility of functionally relevant signature genes in assessing the clinical outcomes of dupilumab treatment in the adult onset atopic dermatitis

Timeline

Start: 2020-09-01
Primary completion: 2022-11-18
Completion: 2022-11-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dupilumab	Monoclonal antibody	—	—

Indications